GLP1R and diabetic cardiomyopathy: Recapitulating the observations reported in humans with T2DM, preclinical studies have also revealed that GLP-1R agonists induce robust cardioprotection (extensively reviewed in Ussher and Drucker, 2014; Drucker, 2016), actions that appear to extend to experimental diabetic cardiomyopathy (Table 2).